【强生靶向口服肽类药物艾特雅在华获批】8月27日,强生公司宣布,白介素23受体拮抗剂艾特雅®已正式获得中国国家药品监督管理局批准,用于适合系统治疗或光疗的中重度斑块状银屑病成人患者和12岁及以上且体重40公斤及以上的儿童患者。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.